Kemble George, Executive Chairman of Sagimet Biosciences Inc. ($SGMT), made one open market sale of company shares in the last year, totaling nearly $290,000. His most recent sale occurred on November 20, 2025. This places him 7,630th among 11,700 insiders in our database by sale value, well below the average of $8.6 million across about six transactions per insider. George recorded no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 20, 2025 | Sagimet Biosciences Inc. | $SGMT | Kemble George | Executive Chairman | S | Series A Common Stock | 37688 | $7.69 | 81,005.0000 | 32,464,893 | 31.75% | 0.12% |
| June 9, 2025 | Sagimet Biosciences Inc. | $SGMT | Kemble George | Director | A | Stock Option (Right to Buy) | 32250 | $0.00 | 32,250.0000 | 32,195,345 | 9999.99% | 0.10% |
| July 23, 2024 | Sagimet Biosciences Inc. | $SGMT | Kemble George | Executive Chairman | S | Series A Common Stock | 23625 | $3.17 | 118,693.0000 | 31,913,887 | 16.60% | 0.07% |
| July 19, 2024 | Sagimet Biosciences Inc. | $SGMT | Kemble George | Executive Chairman | S | Series A Common Stock | 14062 | $3.10 | 142,318.0000 | 31,913,887 | 8.99% | 0.04% |